US 12,274,877 B2
Devices and methods for modulating immune system activity in a cancer patient and treating cancer
Jose M. Carmena, Alameda, CA (US); Michel M. Maharbiz, El Cerrito, CA (US); Ryan Neely, El Cerrito, CA (US); Joshua Kay, Oakland, CA (US); and Giana Montero Garnier, Berkeley, CA (US)
Assigned to IOTA BIOSCIENCES, INC., Alameda, CA (US)
Appl. No. 17/767,409
Filed by Iota Biosciences, Inc., Alameda, CA (US)
PCT Filed Oct. 16, 2020, PCT No. PCT/US2020/056159
§ 371(c)(1), (2) Date Apr. 7, 2022,
PCT Pub. No. WO2021/077020, PCT Pub. Date Apr. 22, 2021.
Claims priority of provisional application 62/916,703, filed on Oct. 17, 2019.
Prior Publication US 2024/0100327 A1, Mar. 28, 2024
Int. Cl. A61N 1/00 (2006.01); A61N 1/36 (2006.01); A61N 1/372 (2006.01); A61N 1/378 (2006.01); A61N 1/05 (2006.01)
CPC A61N 1/36002 (2017.08) [A61N 1/3606 (2013.01); A61N 1/36139 (2013.01); A61N 1/36157 (2013.01); A61N 1/36171 (2013.01); A61N 1/36178 (2013.01); A61N 1/37217 (2013.01); A61N 1/3787 (2013.01); A61N 1/0556 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method of treating a cancer in a subject, comprising:
electrically stimulating the splenic nerve of the subject using a fully implanted device comprising one or more electrodes in electrical communication with the splenic nerve sufficient to increase activation or circulation of natural killer (NK) cells of the subject and treat the cancer in the subject.